Development and validation of an RP-HPLC method for the determination of valacyclovir in tablets and human serum and its application to drug dissolution studies

Journal of Liquid Chromatography and Related Technologies

Volumn 26, Issue 11, 2003, Pages 1755-1767

  Savaşer, Ayhan ^a   Özkan, Cansel K ^a   Özkan, Yalçin ^a   Uslu, Bengi ^b   Özkan, Sibel A ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Determination; Dissolution profile; HPLC; Human serum; Pharmaceuticals; Valacyclovir

Indexed keywords

DISSOLUTION; DRUG DOSAGE; SEPARATION; ULTRAVIOLET DETECTORS;

HUMAN SERUM;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ACICLOVIR; ETODOLAC; VALACICLOVIR;

CHROMATOGRAPHY; CONFERENCE PAPER; DRUG DETERMINATION; DRUG SOLUBILITY; HUMAN; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; SERUM; TABLET; VALIDATION PROCESS;

EID: 0038053037     PISSN: 10826076     EISSN: None     Source Type: Journal    
DOI: 10.1081/JLC-120021283     Document Type: Conference Paper

References (16)

1. Hardman, J.G.; Limbird, L.E. Eds. Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 9th Ed.; The McGraw Hill Co., 1996.
2. Banakar, U.V. Pharmaceutical Dissolution Testing, 1st Ed.; Marcel Dekker Inc.: New York, 1992.
3. Rowe, S.R.; Carless, J.E. Comparison at the in vitro behaviour of various Indomethacin formulations with their in vivo bioavailability. J. Pharm. Pharmacol. 1981, 33, 561-565.
4. Anchisi, C.; Baroli, B.M.; Fadda, A.M.; Manconi, M.; Sinico, C.; Valenti, D. Dissolution properties of flurazepam capsules. Il Farmaco 1998, 53, 662-666.
5. Özkan, Y.; Özkan, S.A.; Aboul-Enein, H.Y. Determination of clenbuterol HCl in human serum and pharmaceuticals and drug dissolution studies by RP-HPLC. J. Liq. Chromatogr. & Rel. Technol. 2001, 24, 679-691.
6. Özkan, S.A.; Özkan, Y.; Aboul-Enein, H.Y. Quality control and drug dissolution studies of pharmaceutical preparations containing cerivastatin sodium by RP-HPLC. J. Liq. Chromatogr. & Rel. Technol. 2002, 25, 251-262.
7. Satiropoulus, B.; Deutsch, T.; Plakogiannis, F.M. Comparative bioavailability of three commercial acetaminophen tablets. J. Pharm. Sci. 1981, 70, 422-425.
8. Pham-Huy, C.; Stathoulopoulou, F.; Sandouk, P.; Scherrmann, J.M.; Palombo, S.; Girre, C. Rapid determination of valacyclovir and acyclovir in human biological fluids by high performance liquid chromatography using isocratic elution. J. Chromatogr. B 1999, 732, 47-53.
9. Weller, S.; Blum, M.R.; Doucette, M.; Burnette, T.; Smiley, M.L.; Cederbeg, D.M.; de Miranda, P. Pharmacokinetics of the acyclovir pro-drug valacyclovir after escalating single and multiple dose administration to normal volunteers. Clin. Pharmacol. Ther. 1995, 54, 595-605.
10. He, Q.; Zhang, Z. Determination of valacyclovir polybutylcyanoacrylate nanoparticles. J. W. China Univ. Med. Sci. 1998, 29, 272-274.
11. The United States Pharmacopoeia, The USP 24th Ed.; Easton, Rand Mc Nally: Tounton, MA, 2000.
12. Higuchi, T. Mechanism of sustained action medication. J. Pharm. Sci. 1963, 52, 1145-1149.
13. Langenbucher, F. Parametric representation of dissolution rate curves by the RRSBW distribution. Pharm. Ind. 1976, 38, 472-477.
14. Krosmeyer, R.W.; Gurny, R.; Doelker, E.; Buri, P.; Peppas, N.A. Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharm. 1983, 15, 25-35.
15. Ritger, P.L.; Peppas, N.A. A simple equation for description of solute release I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J. Cont. Rel. 1987, 5, 23-36.
16. Özdemir, N.; Karataş, A. Effect of shape factor on the release rate of drugs from lipid matrices. Acta Polon. Pharm. Drug. Res. 1997, 54, 353-356.